CD66e / CEA Antibody
299€ (0.1 mg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
CD66e / CEA Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx139357
tested applications
IHC, FCM, IP
Description
CD66e/CEA Antibody is a Mouse Monoclonal against CD66e/CEA.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | CD66e/CEA |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Clone ID | Z677 |
| Purity | > 95% (SDS-PAGE) |
| Purification | Purified by Protein A affinity chromatography. |
| Size 1 | 0.1 mg |
| Tested Applications | IHC, FCM, IP |
| Buffer | PBS solution with 15 mM sodium azide. |
| Availability | Shipped within 5-12 working days. |
| Storage | Store at 2-8°C. Do not freeze. |
| Dry Ice | No |
| UniProt ID | P06731 |
| Gene ID | 1048 |
| Alias | CEA,CD66eMeconium antigen 100,Carcinoembryonic antigen |
| Background | Antibody anti-CEACAM5 |
| Status | RUO |
| Note | Concentration: 1 mg/ml - |
Descripción
CEACAM5, also known as carcinoembryonic antigen (CEA), is a glycoprotein member of the immunoglobulin superfamily that plays a prominent role in cell adhesion, immune modulation, and intercellular signaling. It is highly expressed in epithelial tissues and is overexpressed in various cancers, including colorectal, pancreatic, and lung cancers, where it is used as a tumor marker for diagnosis, prognosis, and monitoring therapeutic responses. CEACAM5 mediates homophilic and heterophilic adhesion, influencing cellular aggregation, invasion, and metastasis. It interacts with other CEACAM family members and cell surface receptors to regulate signaling pathways involved in cell proliferation, migration, and immune evasion. Structurally, CEACAM5 contains multiple immunoglobulin-like domains, a glycosylphosphatidylinositol (GPI) anchor, and extensive glycosylation sites that contribute to its functional diversity. In cancer, CEACAM5 promotes tumor progression by enhancing adhesion to extracellular matrix components and modulating immune responses, such as inhibiting T-cell activation. Therapeutic strategies targeting CEACAM5, including monoclonal antibodies and vaccines, are under development to exploit its role as a biomarker and driver of tumor progression. CEACAM5 also plays roles in physiological processes like epithelial cell polarity and tissue homeostasis, reflecting its multifaceted importance.
Related Products
Recombinant Human CEACAM5
Ver Producto
Recombinant Human CEACAM5
Ver Producto